Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Slideshows|September 11, 2020

6 Sleep Myths: Experts Weigh In

Author(s)Chris Aiken, MD

Ten sleep specialists assessed widely accepted beliefs and here's what they found.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

Andrey Popov/Adobe Stock

FDA Approves Oveporexton for Narcolepsy Type 1, First Drug to Treat Full Range of NT1 Symptoms

ByJessica Walters

August 5th 2026

TNX-102 SL in Major Depressive Disorder: Targeting Slow-Wave Sleep

TNX-102 SL in Major Depressive Disorder: Targeting Slow-Wave Sleep

ByGregory Sullivan, MD

July 29th 2026

Alzheimer

Targeting APOE4: A Promising Therapeutic Strategy for Alzheimer Disease

ByLeah Kuntz,Tri Doan, MD, PhD

July 20th 2026

cataplexy

FDA Accepts NDA for AXS-12 for the Treatment of Cataplexy in Narcolepsy

July 15th 2026

What Clinicians Might Miss in ADHD: Sleep Disorders, Comorbidities, and a Link to Depression

What Clinicians Might Miss in ADHD: Sleep Disorders, Comorbidities, and a Link to Depression

ByAnn Childress, MD

July 11th 2026

Latest CME

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Trending on Psychiatric Times

Experience With Xanomeline/Trospium in an Acute Inpatient Setting Treating Individuals With Schizophrenia

DT120 (Lysergide) Shows Rapid, Lasting Relief for Generalized Anxiety in Phase 3 Trial

Brain Trust: Carl Salzman, MD, on Benzodiazepine Mindful Prescribing, Misuse, and Dependence

Phase 4 Trial of Viloxazine ER Shows Real-World Gains for ADHD With Comorbid Depression, Anxiety

Entactogens as a New Frontier for Mood and Anxiety Disorders: A Conversation With Hiroe Imai Hu, DO, and James W. Murrough, MD, PhD